Masaru Matsuda - 18 Nov 2024 Form 4 Insider Report for Arcutis Biotherapeutics, Inc. (ARQT)

Signature
/s/ David Topper, as Attorney-in-Fact for Masaru Matsuda
Issuer symbol
ARQT
Transactions as of
18 Nov 2024
Net transactions value
-$17,190
Form type
4
Filing time
19 Nov 2024, 19:52:52 UTC
Previous filing
05 Nov 2024
Next filing
04 Feb 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARQT Common Stock Award $0 +4,875 +2.7% $0.000000 183,148 18 Nov 2024 Direct F1
transaction ARQT Common Stock Sale $17,190 -1,775 -0.97% $9.68 181,373 19 Nov 2024 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents the vesting of performance stock units ("PSUs") initially granted on January 3, 2022, that were subject to a performance-based vesting condition. The vesting condition was certified as satisfied on November 18, 2022. The PSUs vest 25% per year on each anniversary of the certification date, subject to the Reporting Person's continued service to the Issuer on such vesting date.
F2 Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the PSUs, the shares were sold upon the vesting of the PSUs solely to cover applicable tax withholdings.
F3 The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $9.22 to $10.09, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Remarks:

Reporting Person's title: Senior Vice President General Counsel and Corporate Secretary